HOUSTON, Sept. 17, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"),
a biopharmaceutical company specializing in the development of
novel treatments for primary and metastatic cancers of the central
nervous system, today announced that CEO, John Climaco, will present virtually at the
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on
Tuesday, September 22nd,
2020 at 10:00 AM EDT.
Oppenheimer Fall
Healthcare Life Sciences & MedTech Summit
|
Date:
|
Tuesday, September
22nd, 2020
|
Time:
|
10:00 AM
EDT
|
Link:
|
http://wsw.com/webcast/oppenheimer5/cnsp/2726100
|
A replay of the presentation will be available on the Company's
website for 90 days following the event. Members of management will
hold 1-on-1 virtual investor meetings at the conference. Investors
attending the conference virtually who are interested in meeting
with Company management should contact their Oppenheimer
representatives.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary and
metastatic cancers of the brain and central nervous system. Its
lead drug candidate, Berubicin, is proposed for the treatment of
glioblastoma multiforme (GBM), an aggressive and incurable form of
brain cancer. CNS holds a worldwide exclusive license to the
Berubicin chemical compound and has acquired all data and know-how
from Reata Pharmaceuticals, Inc. related to a completed Phase 1
clinical trial with Berubicin in malignant brain tumors, which
Reata conducted in 2006. In this trial, 44% of patients
experienced a statistically significant improvement in clinical
benefit. This 44% disease control rate was based on 11 patients
(out of 25 evaluable patients) with stable disease, plus
responders. One patient experienced a durable complete response and
remains cancer-free as of February 20,
2020. These Phase 1 results represent a limited patient
sample size and, while promising, are not a guarantee that similar
results will be achieved in subsequent trials. By the end of 2020,
CNS expects to commence a Phase 2 clinical trial of Berubicin for
the treatment of GBM in the U.S., while a sub-licensee partner
undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial
in pediatric GBM patients in Poland. Its second drug
candidate, WP1244, is a novel DNA binding agent that has shown in
preclinical studies that it is 500 times more potent than the
chemotherapeutic agent daunorubicin in inhibiting tumor cell
proliferation.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-oppenheimer-fall-healthcare-life-sciences--medtech-summit-301132810.html
SOURCE CNS Pharmaceuticals, Inc.